Pace begins trials of cardiac diagnostic
This article was originally published in Clinica
Executive Summary
Canadian diagnostic manufacturer Pace is beginning trials of an ELISA to measure glycogen phosphorylase (GPBB) this month. The earliest known marker detectable in blood following ischaemic damage, GPBB indicates acute myocardial infarction or unstable angina. Patients are being enrolled at three hospitals - one in Canada and two in the US. Pace plans to file a 510(k) for the laboratory test with the US FDA in April.
You may also be interested in...
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says
Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.